You have free access to this content

Cancer

Cover image for Vol. 118 Issue 11

1 June 2012

Volume 118, Issue 11

Pages 2777–2997

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Erratum
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Original Articles

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy (pages 2780–2786)

      Shaheenah Dawood, Asim Jamal Shaikh, Thomas A. Buchholz, Javier Cortes, Massimo Cristofanilli, Sudeep Gupta and Ana M. Gonzalez-Angulo

      Version of Record online: 5 OCT 2011 | DOI: 10.1002/cncr.26579

      • original image
      • original image
      • original image

      We conducted a survey to determine health care workers' perception of the US Food and Drug Administration's (FDA's) decision to remove the indication of bevacizumab for metastatic breast cancer (MBC) to ascertain how it will affect practice and to determine how commonly bevacizumab is used in the community for MBC. Our results highlight the discord between the opinion of community oncologists and the FDA's recent decision to remove the indication of bevacizumab for MBC.

    2. You have free access to this content
      Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer (pages 2787–2795)

      Anne-Renee Hartman, Rajesh R. Kaldate, Lisa M. Sailer, Lisa Painter, Charles E. Grier, Robbin R. Endsley, Marlena Griffin, Stephanie A. Hamilton, Cynthia A. Frye, Mark A. Silberman, Richard J. Wenstrup and John F. Sandbach

      Version of Record online: 5 OCT 2011 | DOI: 10.1002/cncr.26576

      • original image

      The prevalence of BRCA1 mutations in unselected cohorts of patients with triple-negative breast cancer is lower than previously estimated, whereas the prevalence of BRCA2 mutations is likely underestimated. Patients diagnosed with triple-negative breast cancer without any family history of breast or ovarian cancer have a 4% to 5% risk of carrying a mutation in BRCA1 or BRCA2.

    3. You have free access to this content
      Young women with family history of breast cancer and their risk factors for benign breast disease (pages 2796–2803)

      Catherine S. Berkey, Rulla M. Tamimi, Bernard Rosner, A. Lindsay Frazier and Graham A. Colditz

      Version of Record online: 14 NOV 2011 | DOI: 10.1002/cncr.26519

      Adolescent girls with a family history who drink alcohol are at increased risk for benign breast disease (BBD) as young women. Girls with no family history may have different risk factors for BBD.

    4. Endocrine Disease
      You have free access to this content
      Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas : Insights from the largest single-institutional experience (pages 2804–2812)

      Montserrat Ayala-Ramirez, Lei Feng, Mouhammed A. Habra, Thereasa Rich, Paxton V. Dickson, Nancy Perrier, Alexandria Phan, Steven Waguespack, Shreyaskumar Patel and Camilo Jimenez

      Version of Record online: 17 OCT 2011 | DOI: 10.1002/cncr.26577

      • original image

      Systemic chemotherapy may improve blood pressure and reduce tumor size in some patients with metastatic pheochromocytomas and paragangliomas, and it is associated with longer survival.

    5. Gastrointestinal Disease
      You have free access to this content
      Real-time detection of hepatic micrometastases from pancreatic cancer by intraoperative fluorescence imaging : Preliminary results of a prospective study (pages 2813–2819)

      Naoyuki Yokoyama, Tetsuya Otani, Hideki Hashidate, Chiyo Maeda, Tomohiro Katada, Natsuru Sudo, Shoichi Manabe, Yoshinobu Ikeno, Akira Toyoda and Norio Katayanagi

      Version of Record online: 11 OCT 2011 | DOI: 10.1002/cncr.26594

      • original image
      • original image

      Indocyanine green fluorescent imaging is a feasible method for detecting radiographically occult hepatic micrometastases of pancreatic cancer during surgery. In this study, hepatic micrometastases are identified in 16% of patients with pancreatic cancer who undergo surgical exploration and appear to have an adverse clinical impact identical to that of evident distant metastases.

    6. You have free access to this content
      Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer (pages 2820–2827)

      David H. Ilson, Bruce D. Minsky, Geoffrey Y. Ku, Valerie Rusch, Nabil Rizk, Manish Shah, David P. Kelsen, Marinela Capanu, Laura Tang, Jenny Campbell and Manjit Bains

      Version of Record online: 11 OCT 2011 | DOI: 10.1002/cncr.26591

      • original image
      • original image

      Preoperative irinotecan, cisplatin, and radiation therapy in esophageal cancer appeared to offer no advantage over conventional chemoradiotherapy. Early positron emission tomography scan during induction chemotherapy may have predictive and prognostic value, and further evaluation of positron emission tomography scan in this setting is warranted.

    7. You have free access to this content
      Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients (pages 2828–2836)

      Hong-Hee Won, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Jong-Won Kim, Soo-Youn Lee and Se Hoon Park

      Version of Record online: 21 OCT 2011 | DOI: 10.1002/cncr.26614

      • original image

      A genome-wide association analysis identifies potential genetic markers for severe oxaliplatin-induced chronic peripheral neuropathy (OXCPN) in patients with colon cancer. Among the single-nucleotide polymorphisms (SNPs) replicated in a validation sample, 6 SNPs (reference SNP [rs] 10486003 in the tachykinin, precursor 1 [TAC1] gene; rs2338 in the forkhead box C1 [FOXC1] gene; rs830884 in the integrin, alpha 1 [ITGA1] gene; rs843748 in the acylphosphatase 2 [ACYP2] gene; and rs797519 in the deleted in lymphocytic leukemia, 7 [DLEU7] gene) are significant in a model for predicting the occurrence of severe OXCPN.

    8. Genitourinary Disease
      You have free access to this content
      Understanding fragmentation of prostate cancer survivorship care : Implications for cost and quality (pages 2837–2845)

      Ted A. Skolarus, Yun Zhang and Brent K. Hollenbeck

      Version of Record online: 5 OCT 2011 | DOI: 10.1002/cncr.26601

      • original image
      • original image

      Fragmented prostate cancer survivorship care is expensive and associated with potentially unnecessary services. Efforts to improve care coordination via current policy initiatives, electronic medical records, and the implementation of cancer survivorship tools may help to decrease fragmentation of care and mitigate downstream consequences for prostate cancer survivors.

    9. Gynecologic Oncology
      You have free access to this content
      Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma (pages 2846–2857)

      Mohammed Tanjimur Rahman, Kentaro Nakayama, Munmun Rahman, Naomi Nakayama, Masako Ishikawa, Atsuko Katagiri, Kouji Iida, Satoru Nakayama, Yoshiro Otsuki, Ie-Ming Shih and Kohji Miyazaki

      Version of Record online: 2 DEC 2011 | DOI: 10.1002/cncr.26598

      • original image
      • original image
      • original image
      • original image

      ZNF217 overexpression is critical to growth and survival of ovarian clear cell carcinomas with ZNF217 gene amplification as well as most aggressive clinical behavior. This offers ZNF217 as a potential therapeutic target in OCCC patients with ZNF217 amplification.

    10. Head and Neck Disease
      You have free access to this content
      Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma (pages 2858–2871)

      Wei Cao, Zhien Feng, Zhibin Cui, Chenping Zhang, Zhaoyao Sun, Li Mao and Wantao Chen

      Version of Record online: 11 OCT 2011 | DOI: 10.1002/cncr.26575

      • original image
      • original image
      • original image
      • original image
      • original image

      The overexpression of enhancer of zeste homolog 2 (EZH2) frequently correlates positively with cyclin D1 dysregulation and aggressive behaviors in head and neck squamous cell carcinoma. EZH2 may serve as an independent predictor of prognosis in patients with head and neck squamous cell carcinoma. In addition, EZH2 combined with cyclin D1 can serve as a more powerful prognostic predictor for these patients.

    11. You have free access to this content
      Prognosis and risk factors for early-stage adenoid cystic carcinoma of the major salivary glands (pages 2872–2878)

      Mihir K. Bhayani, Murat Yener, Adel El-Naggar, Adam Garden, Ehab Y. Hanna, Randal S. Weber and Michael E. Kupferman

      Version of Record online: 21 OCT 2011 | DOI: 10.1002/cncr.26549

      • original image
      • original image

      Certain high-risk features are predictive for the development of distant metastasis in early-stage adenoid cystic carcinoma. Ultimately, these features will lead to a more personalized treatment approach and consideration for systemic therapy for those patients who are at high risk for distant metastasis.

    12. Hematologic Malignancies
      You have free access to this content
      Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53 (pages 2879–2888)

      Rashmi Kanagal-Shamanna, Carlos E. Bueso-Ramos, Bedia Barkoh, Gary Lu, Sa Wang, Guillermo Garcia-Manero, Saroj Vadhan-Raj, Daniela Hoehn, L. Jeffrey Medeiros and C. Cameron Yin

      Version of Record online: 28 OCT 2011 | DOI: 10.1002/cncr.26537

      • original image
      • original image

      The authors assess the clinicopathologic, immunophenotypic, and molecular genetic features of 22 myeloid neoplasms with isolated isochromosome 17q. They conclude that myeloid neoplasms with isolated isochromosome 17q represent a distinct clinicopathologic entity with myelodysplastic and myeloproliferative features, wild-type TP53, and high risk of leukemic transformation.

    13. Lung Disease
      You have free access to this content
      Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome (pages 2889–2899)

      Luisa M. Solis, Carmen Behrens, M. Gabriela Raso, Heather Y. Lin, Humam Kadara, Ping Yuan, Hector Galindo, Ximing Tang, J. Jack Lee, Neda Kalhor, Ignacio I. Wistuba and Cesar A. Moran

      Version of Record online: 21 OCT 2011 | DOI: 10.1002/cncr.26584

      • original image
      • original image
      • original image

      In patients with primary lung adenocarcinoma, the presence of any percentage of histologic solid pattern is a marker of an unfavorable prognosis. In those who have tumors with nonsolid histologic growth patterns, high expression of thyroid transforming growth factor 1 and low scores on a panel of 5 proteins (referred to as the FILM signature index) are associated with a better prognosis.

    14. Soft Tissue and Bone Sarcoma
      You have free access to this content
      Sarcoma metastases to the skin : A clinicopathologic study of 65 patients (pages 2900–2904)

      Wei-Lien Wang, Ross A. Bones-Valentin, Victor G. Prieto, Raphael E. Pollock, Dina C. Lev and Alexander J. Lazar

      Version of Record online: 11 OCT 2011 | DOI: 10.1002/cncr.26590

      • original image

      Cutaneous metastatic sarcoma is rare, occurs late in the course of the disease, and heralds a poor prognosis. Because metastatic leiomyosarcoma is the most common source of these metastases, clinical correlation is needed before a diagnosis of primary cutaneous sarcoma can be established.

    15. You have free access to this content
      High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes (pages 2905–2914)

      Edwin Choy, Francis Hornicek, Laura MacConaill, David Harmon, Zeeshan Tariq, Levi Garraway and Zhenfeng Duan

      Version of Record online: 17 OCT 2011 | DOI: 10.1002/cncr.26617

      • original image
      • original image

      Understanding the genetic basis for osteosarcoma may lead to therapeutic advances for patients with this disease. Here, the authors use a high-throughput genotyping platform to perform the largest mutational analysis of osteosarcoma to date, uncovering mutations in phosphoinositide-3-kinase and other oncogenes and tumor suppressor genes.

    16. Discipline

      Clinical Trials
      You have free access to this content
      Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide (pages 2915–2924)

      Giordano Savelli, Francesco Bertagna, Fabio Franco, Ludovica Dognini, Giovanni Bosio, Elena Migliorati, Carlo Rodella, Giorgio Biasiotto, Giovanni Bettinsoli, Chiara Minari, Alberto Zaniboni, Chiara Ferrari, Paola Tomassetti, Vittorio Ferrari and Raffaele Giubbini

      Version of Record online: 21 OCT 2011 | DOI: 10.1002/cncr.26616

      • original image
      • original image
      • original image

      Peptide receptor radionuclide therapy (PRRT) is effective in the treatment of advanced stage neuroendocrine carcinomas. The effectiveness of PRRT may be enhanced by its use at an earlier stage of disease.

    17. Disparities Research
      You have free access to this content
      Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults (pages 2925–2934)

      Christina D. Mack, William Carpenter, Anne-Marie Meyer, Hanna Sanoff and Til Stürmer

      Version of Record online: 9 NOV 2011 | DOI: 10.1002/cncr.26622

      • original image
      • original image
      • original image

      Medicare-insured African Americans with stage III colon cancer are not less likely to receive the novel recommended chemotherapy, oxaliplatin, than Caucasian Americans. African Americans may even benefit more than Caucasian Americans from this treatment.

    18. Medical Oncology
      You have free access to this content
      Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil–based chemotherapy (pages 2935–2943)

      Yvonne Wettergren, Göran Carlsson, Elisabeth Odin and Bengt Gustavsson

      Version of Record online: 21 OCT 2011 | DOI: 10.1002/cncr.26595

      • original image

      Pretherapeutic urinary uracil and dihydrouracil levels may be related to risk of side effects during adjuvant 5-fluorouracil–based treatment of patients with colorectal cancer. Sex is a strong risk factor for toxicity, showing the importance of evaluating male and female patients separately.

    19. Outcomes Research
      You have free access to this content
      Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era : Findings from a large national database (pages 2944–2951)

      Anita Kumar, Ann Vanderplas, Ann S. LaCasce, Maria A. Rodriguez, Allison L. Crosby, Eva Lepisto, Myron S. Czuczman, Auayporn Nademanee, Joyce Niland, Leo I. Gordon, Michael Millenson, Andrew D. Zelenetz, Jonathan W. Friedberg and Gregory A. Abel

      Version of Record online: 17 OCT 2011 | DOI: 10.1002/cncr.26588

      • original image
      • original image

      The authors characterize patterns of central nervous system (CNS) prophylaxis and outcomes in patients with diffuse large B-cell lymphoma who receive combined rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone using the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes Database, a prospective cohort study that collects clinical and outcomes data from 7 participating centers. The results indicate a low rate of CNS recurrence and no prophylaxis-associated survival benefit, which calls into question the utility of CNS prophylaxis in the rituximab era.

    20. Pathology
      You have free access to this content
      Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma (pages 2952–2961)

      Steven Chuan-Hao Kao, Nicola Armstrong, Bridget Condon, Kim Griggs, Brian McCaughan, Sarah Maltby, Alan Wilson, Douglas W. Henderson and Sonja Klebe

      Version of Record online: 21 OCT 2011 | DOI: 10.1002/cncr.26497

      • original image
      • original image
      • original image
      • original image

      Malignant mesothelioma is an aggressive pleural tumor with poor prognosis and few defined prognostic factors. Based on 2 independent cohorts of patients, aquaporin 1 emerges as a new and independent prognostic factor.

    21. Radiation Oncology
      You have free access to this content
      Stereotactic body radiotherapy for multisite extracranial oligometastases : Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease (pages 2962–2970)

      Joseph K. Salama, Michael D. Hasselle, Steven J. Chmura, Renuka Malik, Neil Mehta, Kamil M. Yenice, Victoria M. Villaflor, Walter M. Stadler, Philip C. Hoffman, Ezra E. W. Cohen, Philip P. Connell, Daniel J. Haraf, Everett E. Vokes, Samuel Hellman and Ralph R. Weichselbaum

      Version of Record online: 21 OCT 2011 | DOI: 10.1002/cncr.26611

      • original image
      • original image

      Patients with 1 to 5 sites of limited volume metastatic disease receive escalating doses of stereotactic body radiotherapy to all metastatic sites. The maximal tolerated dose is not reached in any cohort. After treatment, a subset of patients do not experience metastatic progression, and those patients with metastatic progression typically do so in limited number and location, suggesting that metastasis-directed therapy (potentially with stereotactic body radiotherapy) be considered for oligometastatic patients.

    22. You have free access to this content
      Completion of and early response to chemoradiation among human immunodeficiency virus (HIV)-positive and HIV-negative patients with locally advanced cervical carcinoma in South Africa (pages 2971–2979)

      Hannah M. Simonds, Jason D. Wright, Naomi du Toit, Alfred I. Neugut and Judith S. Jacobson

      Version of Record online: 9 NOV 2011 | DOI: 10.1002/cncr.26639

      • original image

      Human immunodeficiency virus-positive cervical cancer patients present at an earlier age, with more advanced disease. Early response in this subgroup of patients depends on stage of disease and completion of adequate radiation.

    23. You have free access to this content
      Single brain metastasis: Radiosurgery alone compared with radiosurgery plus up-front whole-brain radiotherapy (pages 2980–2985)

      Dirk Rades, Dagmar Hornung, Theo Veninga, Steven E. Schild and Jan Gliemroth

      Version of Record online: 25 OCT 2011 | DOI: 10.1002/cncr.26612

      • original image
      • original image
      • original image

      Data of 63 patients who received radiosurgery (RS) alone for a single brain metastasis were retrospectively compared with 39 patients treated with whole-brain radiotherapy (WBRT) plus RS for treatment outcomes. The addition of WBRT to RS was associated with improved local control of the treated metastasis and distant intracerebral control but not survival.

    24. Translational Research
      You have free access to this content
      Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis : An experimental study (pages 2986–2996)

      Li-Hua Shao, Shao-Ping Liu, Jin-Xuan Hou, Yan-Hua Zhang, Chun-Wei Peng, Yan-Jun Zhong, Xiong Liu, Xiu-Li Liu, Ya-Ping Hong, Raymond A. Firestone and Yan Li

      Version of Record online: 17 OCT 2011 | DOI: 10.1002/cncr.26596

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Doxorubicin (Adriamycin) is an effective but toxic chemotherapy drug. This modified prodrug Ac-Phe-Lys-PABC-ADM retains the good efficacy of doxorubicin and reduces severe side effects.

  3. Erratum

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Erratum
    1. You have free access to this content

SEARCH

SEARCH BY CITATION